ClinicalTrials.gg
Not yet recruitingNCT05826834Updated Jul 3, 2023

An Investigation of Ball Rolling Effects on Trigger Points

An interventional study of ball-rolling (Myostorm ball) in Trigger Point Pain, Myofascial, sponsored by Memorial University of Newfoundland. Not yet recruiting. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by Memorial University of Newfoundland · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The current study aims to examine the potential effects of rolling a Myostorm ball on the trigger points in the upper back muscles.

Read the detailed description

The investigators will ask the participants to attend the laboratory in two sessions. They will seek the tender spots on the trapezius muscle. Then the participants will be asked to roll a Myostorm ball ( a small hard ball made of plastic with a layer of soft material cover) on their affected muscles. They will be tested for pain-pressure threshold (PPT), shoulder range of motion, electromyography (EMG), and force before and after the manipulation.

02

Conditions studied

  • Trigger Point Pain, Myofascial
03

In context

Myofascial Pain Syndromes

339 studies on the registry are indexed under Myofascial Pain Syndromes; 66 are open to participants now.

This study's planned enrollment of 20 is below the median of 50 across 307 interventional studies indexed under Myofascial Pain Syndromes.

Browse Myofascial Pain Syndromes studies →

Lead sponsor

Memorial University of Newfoundland is the lead sponsor of 49 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • trigger points on the trapezius muscle

Exclusion criteria

Exclusion Criteria:

  • back injury
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Ball rolling

    The ball-rolling group will be asked to roll the ball on the trapezius muscle.

    Device: ball-rolling (Myostorm ball)

  • No intervention
    Control

    The control group with no intervention

Interventions

  • Deviceball-rolling (Myostorm ball)

    the intervention group

06

What researchers measure

Primary outcomes

  1. Range of Motion before ball rolling

    the range of motion in the shoulder joint

    Time frame: 3 minutes before the intervention (Ball-rolling)

  2. Pain pressure threshold before ball rolling

    the measurement of the pain pressure threshold on the trapezius muscle using Lafayette Muscle Tester; A hand-held algometer will be applied on the participant's skin and an incremental pressure will be applied until the participant notify the experimenter to stop. The pain pressure threshold will be reported in kilogram/cm2.

    Time frame: 3 minutes before the intervention (Ball-rolling)

  3. Range of Motion after ball rolling

    the range of motion in the shoulder joint

    Time frame: up to 3 minutes after the intervention (Ball-rolling)

  4. Pain pressure threshold after ball rolling

    the measurement of the pain pressure threshold on the trapezius muscle using Lafayette Muscle Tester; A hand-held algometer will be applied on the participant's skin and an incremental pressure will be applied until the participant notify the experimenter to stop. The pain pressure threshold will be reported in kilogram/cm2.

    Time frame: up to 3 minutes after the intervention (Ball-rolling)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — The data will be kept confidential, and the participant codes will be used to link individual data across the experiment sessions. Data will be stored physically and digitally in Dr. Behm's office. Every reasonable effort will be made to ensure the participants' anonymity. They will not be identified in publications without their explicit permission. All data will be collected independently and kept confidential. All data will be stored in hardcopy and password-protected digital copy in Dr. David Behm's office at the Memorial University of Newfoundland. Consent forms will be stored separately from participant data in a locked cabinet in Dr. David Behm's office. Data access will be limited only to our research team members. Data potentially may be published in an online journal article. Published data will contain no personally identifying information.

Supporting information: Clinical study report

Time frame: Data will be kept for at least five years, as Memorial University's policy on Integrity in Scholarly Research requires.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Dec 2023, 5 months later.

Of 202 non-industry interventional studies with no phase under Myofascial Pain Syndromes, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's planned 5 months is close to that.

Counting every sponsor, half of 204 studies reached it within 5 months; a quarter within 2 and three quarters within 13.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2023
First posted
Apr 24, 2023
StartEst.
Jul 2023
Primary completionEst.
Dec 2023
CompletionEst.
Feb 2024
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05826834
Lead sponsor
Memorial University of Newfoundland
Collaborators
Mitacs
Responsible party
Saman Anvar (Principal Investigator, Memorial University of Newfoundland) — Principal investigator
First posted
Apr 24, 2023
Start date
Jul 2023 (estimated)
Primary completion
Dec 2023 (estimated)
Completion
Feb 2024 (estimated)
Last update
Jul 3, 2023

Study contacts

Saman H Anvar
Contact
SHADJIZADEHA@MUN.CA
7092194733
David Behm
Contact
DBEHM@MUN.CA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion